drugset / Trial / NCT01114139

A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia

NCT01114139

Phase 3 Completed 812 enrolled AMAG Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared with placebo for the treatment of iron deficiency anemia (IDA).

Timeline

Start
2010-06-19
Primary completion
2012-02-27
Completion
2012-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferumoxytol Diagnostic / imaging agent 510 mg Intravenous